🔗 Share this article

Given that the United States undertakes unprecedented changes to its vaccination schedules, an unexpected name has emerged somewhat surprisingly: Dr. Tracy Beth Høeg, an American of Danish descent sports physician and public health researcher who first made her name by expressing skepticism about Covid shots during the global health crisis and has zeroed in on possible deaths following COVID-19 immunization in her recent tenure at the US Food and Drug Administration (FDA).

Planned Overhauls to Childhood Immunization Program

Public health authorities had intended to reveal radical revisions to the pediatric immunization program earlier this month, aligning the US with Denmark’s immunization schedule, sources say – a significant shift that would put the US out of step with much of the international standard with no evidence for benefit. The planned update has been pushed back until the new year.

In place of Vinay Prasad, Høeg is listed to address the audience at the event. She was newly appointed interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to head the office this year.

A New Direction at the Agency

The acting appointment may indicate a strengthened alliance between the drug and vaccine branches as Høeg and Dr. Prasad strengthen their influence at the agency – and it signals a renewed priority upon rolling back long-standing immunizations at the FDA.

Høeg has repeatedly called for halting certain childhood vaccine recommendations in the US to become more similar to the Danish model, a country with nationalized medicine and a number of inhabitants approximately the size of the state of Wisconsin.

So far comments, she has kept her attention on vaccines – usually the domain of Dr. Prasad, chief of the FDA’s CBER – rather than medication approval.

Questions Over Qualifications

Dr. Høeg has no obvious track record in pharmaceutical research, regulation or administrative roles, which has been standard for former directors of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a top consultant to the agency head and CBER since earlier this year.

“It seems she lacks to have any of the qualifications” for overseeing the pharmaceutical oversight division, remarked Jonathan Howard. “She’s never run a randomized controlled trial. She has no expertise in leading a major agency. She has no expertise in pharmaceutical oversight.”

Past directors of CBER would “grasp laws and regulations and the science of medication creation”, noted Janet Woodcock. “Objectively, she lacks the kind of background that previous people who led the center have had.”

The drug center has an vast portfolio at the FDA, Woodcock emphasized.

“Many people just pays attention on the novel medication approvals, but the generic drug division approves thousands of off-brand pharmaceuticals. There’s a biologic copycat branch, over-the-counter program and so forth, and all of those must be supervised,” Dr. Woodcock explained. “The thing you neglect, that is the part that I always told people is going to come back to haunt you.”

Furthermore, a major administrative element to the position, which manages in excess of 5,000 personnel. “It’s a massive administrative position, if you execute it properly,” the former official added.

Agency Reaction and Disputed Programs

In response to questions about Høeg’s fitness for the role and whether this assignment indicates greater collaboration among regulatory chiefs on immunizations, a representative responded that the “inquiries are based on inaccurate presumptions”.

“This background aligns with the duties of her job,” the official said, noting the time Høeg spent counseling the agency head on “drug safety and regulatory science, including predictive safety algorithms and immunization monitoring”.

As the temporary head, Høeg assumes responsibility for the agency head's recently launched expedited review system, a disputed rapid medication authorization process that reportedly troubled her former heads. “How are these therapies being picked for this fast-track system? Who makes the calls?” Howard asked. “There is a lot of lack of transparency occurring at the agency right now.”

In general, he remarked, “the FDA looks to be trending towards less stringent rules of most medications, except for immunizations.”

Public Track Record on Vaccines

Regarding vaccines, Høeg has a more documented, if troubling, history, Howard observe. She authored a analysis using unconfirmed volunteer-provided data to determine the incidence of heart inflammation after Covid immunization. She consulted for the Florida top health official Joseph Ladapo, who allegedly have altered data to suggest Covid vaccinations are more dangerous than they are.

Included in her “desired changes” for the current federal leadership featured altering regulations for recently developed shots and discontinuing “unnecessary” vaccines, she stated after the election on a podcast. At the FDA, Dr. Høeg has reportedly proposed barring teenage boys from receiving Covid vaccinations.

“She’s an all-around ideologue who begins with her beliefs and tailors the evidence to retrofit the evidence in a very deceptive, dishonest way,” Howard argued.

Taking Control and a “Push for Payback”

Dr. Høeg became part of fellow skeptics, {like|